UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Metabolic Effects and Good Tolerance of IVA337 a Pan-Ppar Agonist in Diabetic Patients Warrant Further Investigation in Nash

Journal of hepatology, 2016, Vol.64 (2), p.S189-S189

2016

Volltextzugriff (PDF)

IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis

Journal of hepatology, 2017, Vol.66 (1), p.S171-S171

2017

Volltextzugriff (PDF)

AB0206 Pan-Ppar Agonist IVA337 is Effective in Prevention and Treatment of Experimental Skin Fibrosis

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.959-960

2015

Volltextzugriff (PDF)

594 Identification of novel EZH2 inhibitor scaffolds

European journal of cancer (1990), 2014-11, Vol.50, p.191-191

2014

Volltextzugriff (PDF)

557 A rational approach for discovery of inhibitors of YAP-TEAD interaction

European journal of cancer (1990), 2014-11, Vol.50, p.180-180

2014

Volltextzugriff (PDF)

Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism

Molecular and cellular endocrinology, 2001-12, Vol.185 (1), p.195-204

2001

Volltextzugriff (PDF)

GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6

Journal of medicinal chemistry, 2001-02, Vol.44 (3), p.453-467

2001

Volltextzugriff (PDF)

PS105 - Metabolic Effects and Good Tolerance of IVA337 a Pan-Ppar Agonist in Diabetic Patients Warrant Further Investigation in Nash

Journal of hepatology, 2016, Vol.64 (2), p.S189-S189

2016

Volltextzugriff (PDF)

Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures

Behavioural pharmacology, 1995-04, Vol.6 (3), p.215-222

1995

Volltextzugriff (PDF)

THU-391 - IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis

Journal of hepatology, 2017, Vol.66 (1), p.S171-S171

2017

Volltextzugriff (PDF)

Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats

Diabetes (New York, N.Y.), 2002-05, Vol.51 (5), p.1461-1469

2002

Volltextzugriff (PDF)

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

The Journal of pharmacology and experimental therapeutics, 2002-04, Vol.301 (1), p.95

2002

Volltextzugriff (PDF)

PS068 - The New Generation Pan-Ppar Agonist Iva337 Protects the Liver from Metabolic Disorders and Fibrosis

Journal of hepatology, 2016, Vol.64 (2), p.S169-S170

2016

Volltextzugriff (PDF)

L’agoniste pan-PPAR IVA337 est efficace pour la prévention de la fibrose pulmonaire et de l’hypertension pulmonaire expérimentales

Revue du rhumatisme (Ed. française : 1993), 2016-11, Vol.83, p.A105-A106

2016

Volltextzugriff (PDF)

Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype

Endocrinology (Philadelphia), 1999-09, Vol.140 (9), p.4046-4055

1999

Volltextzugriff (PDF)

Trans N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]cycloprop-2-ene-1-carboxamides : Novel lipophilic kappa opioid agonists

Bioorganic & medicinal chemistry letters, 1997-02, Vol.7 (3), p.291-296

1997

Volltextzugriff (PDF)

Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes

Endocrinology (Philadelphia), 2000-12, Vol.141 (12), p.4419

2000

Volltextzugriff (PDF)

Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance

European journal of pharmaceutics and biopharmaceutics, 2004-05, Vol.57 (3), p.441-446

2004

Volltextzugriff (PDF)

Antidepressant/anxiolytic ipsapirone inhibits cold-induced hypothalamic TRH release

Neuroreport, 1993-09, Vol.4 (10), p.1200-1202

1993

Volltextzugriff (PDF)

Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach

The American journal of pathology, 2001-08, Vol.159 (2), p.753-764

2001

Volltextzugriff (PDF)

Stimulation of the Gonadotropic Axis by the Neuropeptide Y Receptor Y1 Antagonist/ Y4 Agonist 1229U91 in the Male Rat

Neuroendocrinology, 2000-01, Vol.71 (1), p.2-7

2000

Volltextzugriff (PDF)

Antinociceptive effects of neuropeptide Y and related peptides in mice

Brain research, 1996-06, Vol.724 (1), p.25-32

1996

Volltextzugriff (PDF)

transN-Methyl- N-[2-(1-pyrrolidinyl)cyclohexyl] cycloprop-2-ene-1-carboxamides: Novel lipophilic kappa opioid agonists

Bioorganic & medicinal chemistry letters, 1997, Vol.7 (3), p.291-296

1997

Volltextzugriff (PDF)

The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine

European neuropsychopharmacology, 1998-12, Vol.8 (4), p.261-266

1998

Volltextzugriff (PDF)

Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats

Biological psychiatry (1969), 1992-02, Vol.31 (4), p.391-400

1992

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(56)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Animals
(24)
Male
(21)
Rats
(18)
Biological And Medical Sciences
(13)
Pharmacology & Pharmacy
(12)
Medical Sciences
(8)
Rats, Sprague-Dawley
(8)
Humans
(7)
Neurosciences
(7)
Neurosciences & Neurology
(7)
Pharmacology. Drug Treatments
(7)
Female
(6)
Life Sciences
(6)
Corticosterone - Blood
(5)
Dose-Response Relationship, Drug
(5)
Endocrinology & Metabolism
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Glucose
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolic Effects and Good Tolerance of IVA337 a Pan-Ppar Agonist in Diabetic Patients Warrant Further Investigation in Nash

IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis

AB0206 Pan-Ppar Agonist IVA337 is Effective in Prevention and Treatment of Experimental Skin Fibrosis

594 Identification of novel EZH2 inhibitor scaffolds

557 A rational approach for discovery of inhibitors of YAP-TEAD interaction

Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism

GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6

PS105 - Metabolic Effects and Good Tolerance of IVA337 a Pan-Ppar Agonist in Diabetic Patients Warrant Further Investigation in Nash

Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures

THU-391 - IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis

Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

PS068 - The New Generation Pan-Ppar Agonist Iva337 Protects the Liver from Metabolic Disorders and Fibrosis

L’agoniste pan-PPAR IVA337 est efficace pour la prévention de la fibrose pulmonaire et de l’hypertension pulmonaire expérimentales

Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype

Trans N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]cycloprop-2-ene-1-carboxamides : Novel lipophilic kappa opioid agonists

Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes

Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance

Antidepressant/anxiolytic ipsapirone inhibits cold-induced hypothalamic TRH release

Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach

Stimulation of the Gonadotropic Axis by the Neuropeptide Y Receptor Y1 Antagonist/ Y4 Agonist 1229U91 in the Male Rat

Antinociceptive effects of neuropeptide Y and related peptides in mice

transN-Methyl- N-[2-(1-pyrrolidinyl)cyclohexyl] cycloprop-2-ene-1-carboxamides: Novel lipophilic kappa opioid agonists

The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine

Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats

Suchergebnisse filtern